Literature DB >> 26950381

Autologous and allogeneic stem cell transplant in Jehovah's Witnesses: a single-center experience on 22 patients.

P Mazza1, G Palazzo1, C Minoia1, B Amurri1, G Pisapia1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26950381     DOI： 10.1038/bmt.2016.29

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

1.  Successful autologous bone marrow transplant without the use of blood product support.

Authors:  K K Ballen; P A Ford; H Waitkus; R V Emmons; W Levy; P Doyle; F M Stewart; P J Quesenberry; P S Becker
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

2.  Bone marrow transplantation in Jehovah's Witnesses.

Authors:  Melissa Rubenstein; Madeleine Duvic
Journal:  Leuk Lymphoma       Date:  2004-03

3.  The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products.

Authors:  S Ciurea; R Beri; L Dobogai; S Chunduri; N Mahmud; D Rondelli; D Peace
Journal:  Bone Marrow Transplant       Date:  2006-02       Impact factor: 5.483

4.  Autologous stem cell transplants in Jehovah's Witnesses.

Authors:  N M Brown; S Y Kim; P A Ford
Journal:  Bone Marrow Transplant       Date:  2009-03-23       Impact factor: 5.483

5.  Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.

Authors:  E Hermet; A Cabrespine; R Guièze; A Garnier; A Tempescul; P Lenain; R Bouabdallah; J P Vilque; J Frayfer; D Bordessoule; D Sibon; M Janvier; D Caillot; P Biron; L Legros; B Choufi; B Drenou; N C Gorin; K Bilger; J Tamburini; C Soussain; S Brechignac; J O Bay
Journal:  J Geriatr Oncol       Date:  2015-06-23       Impact factor: 3.599

6.  A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

Authors:  Avichai Shimoni; Irit Avivi; Jacob M Rowe; Moshe Yeshurun; Itai Levi; Reuven Or; Paulina Patachenko; Abraham Avigdor; Tzila Zwas; Arnon Nagler
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

7.  Autologous stem-cell transplantation can be performed safely without the use of blood-product support.

Authors:  Karen K Ballen; Pamela S Becker; Beow Yong Yeap; Barbara Matthews; David H Henry; Patricia A Ford
Journal:  J Clin Oncol       Date:  2004-09-07       Impact factor: 44.544

8.  Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience.

Authors:  P Mazza; A Prudenzano; B Amurri; G Palazzo; G Pisapia; L Stani; G Pricolo
Journal:  Bone Marrow Transplant       Date:  2003-08       Impact factor: 5.483

9.  Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness.

Authors:  T Zenz; H Döhner; D Bunjes
Journal:  Bone Marrow Transplant       Date:  2003-08       Impact factor: 5.483
  9 in total
  1 in total

Review 1.  Physician autonomy and patient rights: lessons from an enforced blood transfusion and the role of patient blood management.

Authors:  Matteo Bolcato; Aryeh Shander; James P Isbister; Kevin M Trentino; Marianna Russo; Daniele Rodriguez; Anna Aprile
Journal:  Vox Sang       Date:  2021-04-07       Impact factor: 2.996
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.